aldosterone synthase inhibitor

Lorundrostat Lowers 24‑Hour Systolic Blood Pressure in Treatment‑Resistant Hypertension but Raises Hyperkalemia Concerns

By MedXY 12/06/2025

A randomized, placebo‑controlled trial found lorundrostat reduced 24‑hour systolic BP by ~7–8 mm Hg versus placebo in patients with uncontrolled, treatment‑resistant hypertension; notable rates of marked hyperkalemia occurred only in active treatment groups.

Cardiology Specialties

Baxdrostat: A Promising New Agent for Managing Uncontrolled and Resistant Hypertension

By MedXY 09/11/2025

Baxdrostat, a novel aldosterone synthase inhibitor, significantly reduces systolic blood pressure in patients with uncontrolled or resistant hypertension, offering a new therapeutic option with a favorable safety profile.

Cardiology Clinical Updates news Specialties

Lorundrostat: A New Frontier in the Management of Uncontrolled and Treatment-Resistant Hypertension

By MedXY 08/09/2025

Lorundrostat, an aldosterone synthase inhibitor, significantly reduced systolic blood pressure in adults with uncontrolled and treatment-resistant hypertension, demonstrating efficacy and safety as an adjunct therapy.